UK robotics companies have raised $258 million during 2026, putting the sector ahead of the $150 million recorded for the whole of 2025 and the $51 million raised during 2024, according to figures published from Tracxn Technologies’ UK robotics dataset.
Tracxn Technologies counts 357 robotics companies in the UK ecosystem, with cumulative equity funding of approximately $2.2 billion. This year’s $258 million has been raised across 12 rounds, compared with eight rounds during 2025 and 19 during 2024.
The higher total therefore reflects larger investments rather than a broad increase in transaction volume. Humanoid’s $152 million Series A and Automata’s $45 million Series C together account for 76% of all UK robotics funding recorded so far this year.
London-based Humanoid completed its Series A in July at a $1.35 billion post-money valuation, bringing total capital raised by the company to $270 million. Investors included Schaeffler and Bosch alongside Prime Movers Lab, Fubon Financial Holding Venture Capital, and Aglaé Ventures.
The company intends to use the capital for next-generation robot development, software, commercial deployment, and the start of mass manufacturing for wheeled humanoid systems. Industrial customers already form part of that plan rather than sitting solely in a future sales pipeline.
Humanoid has signed a phased deployment and supply agreement with Schaeffler covering a four-digit number of wheeled robots across global facilities by 2032. Initial systems are scheduled to enter live German manufacturing environments during late 2026, while Schaeffler will also supply actuators for the robots.
Bosch has a different role. Following a joint industrial proof of concept, it has agreed to act as Humanoid’s contract manufacturing partner for HMND 01 robots intended for the European market, providing expertise around hardware design, production, supply chain, reliability, serviceability, and cost.
Automata’s $45 million Series C, announced in January, addresses another part of the robotics market. The company develops automated laboratory infrastructure combining robotics, orchestration software, and data systems, with the latest capital intended to expand an operating model built around AI-ready life-sciences laboratories.
The contrast between the two businesses shows how broadly robotics investment is now being defined. Humanoid is pursuing mobile machines for logistics and production environments; Automata combines robots and software inside laboratories where repeatable sample handling and data integration are the principal requirements.
Both companies also demonstrate why the funding figures need careful interpretation. Removing their combined $197 million leaves approximately $61 million distributed across the other ten rounds recorded during the year. The national total has risen sharply, but the capital market remains highly concentrated.
Geography shows a similar imbalance. Tracxn’s figures put Cambridge at $1.3 billion of cumulative robotics funding across 12 companies and 13 rounds, while London accounts for $582 million across 103 companies and 75 rounds. A larger number of businesses therefore does not necessarily correspond with a larger share of invested capital.
Large robotics funding rounds can absorb cash quickly because industrialisation requires considerably more than software development. Robots need actuators, drives, sensors, compute hardware, batteries, safety systems, mechanical components, manufacturing tooling, test processes, integration engineering, and field support. Reliability has to improve while unit cost falls, and both objectives become harder once equipment leaves controlled demonstrations and enters continuous production environments.
Humanoid’s relationships with Bosch and Schaeffler connect its financing directly to those manufacturing problems. Contract production reduces the need to build an entire factory organisation internally, while a strategic component supplier can influence design-for-manufacture and supply availability before production volumes rise.
Automata faces a different industrialisation problem but a similar need for repeatability. Laboratory automation only creates value if instruments from different suppliers can be integrated reliably, workflows remain traceable, and software can accommodate changes without requiring expensive bespoke re-engineering each time the science changes.
The $258 million headline therefore describes two trends at once. Capital has returned to UK robotics at a higher level than in either of the previous two years, while investors have concentrated most of that increase into businesses already showing manufacturing partnerships, defined applications, or routes towards commercial deployment.
Installed systems will provide the harder measure over the remainder of the year. Humanoid expects initial factory deployments in Germany before the end of 2026, while Automata is using its Series C to expand laboratory deployments. If those programmes scale, the funding figures will begin to translate into industrial output; until then, most of the year’s apparent robotics boom remains concentrated in two unusually large cheques.
